AI-Powered Solutions Aim to Prevent 80% of Cardiovascular Deaths

Cardiovascular disease (CVD) remains the leading cause of death in the United States, yet an estimated 80% of cases are preventable through early detection and proactive risk management. This statistic underscores the critical need for innovative tools that can identify risk earlier and guide personalized interventions. Cardio Diagnostics Holdings (NASDAQ: CDIO) is addressing this need with a suite of clinical, population health, and biopharma solutions that leverage artificial intelligence (AI), epigenetics, and genetics to improve cardiovascular disease prevention, detection, and management.

The company’s platform integrates genetic and epigenetic biomarkers with AI-driven analytics to deliver personalized cardiovascular insights from blood-based testing. Cardio Diagnostics currently offers two clinical solutions: Epi+Gen CHD™ and PrecisionCHD™. These tools aim to identify risk earlier and tailor intervention strategies, aligning with growing recognition that early prevention can significantly improve long-term outcomes. By targeting multiple stages of care—from prevention to management—the company reflects a comprehensive strategy to combat CVD.

This emphasis on prevention is particularly relevant given that many risk factors are modifiable. Cardio Diagnostics’ approach not only empowers healthcare providers with actionable data but also has the potential to reduce healthcare costs and improve patient quality of life. As the company continues to develop its platform, it positions itself at the forefront of precision medicine in cardiology. For more details, read the full release on NEWMEDIAWIRE.